

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the claims:

Claims 1-26 (canceled)

Claim 27 (currently amended): A method for enhancing efficacy of a chemotherapeutic agent for a cancer cell, said method comprising administering ~~systemically~~ intravenously to a subject in need thereof an effective amount of hyaluronan and said chemotherapeutic agent, wherein the hyaluronan has a ~~molar~~ molecular weight of between 750,000 and 890,000 Da, with an intrinsic viscosity of between 11.07dl/gm and 12.45 dl/gm.

Claims 28-29 (canceled)

Claim 30 (previously presented): The method according to Claim 27, wherein the hyaluronan has a molecular weight of 890,000 Da.

Claim 31 (canceled)

Claim 32 (previously presented): The method according to Claim 27, wherein the chemotherapeutic agent is selected from the group consisting of methotrexate, paclitaxel, 5-fluorouracil and cyclophosphamide or combinations thereof.

Claim 33 (currently amended): A method for enhancing efficacy of a chemotherapeutic agent for a cancer cell, said method comprising administering ~~systemically~~ intravenously to a subject in need thereof an effective amount of a composition consisting essentially of hyaluronan and said chemotherapeutic agent, wherein the hyaluronan has a ~~molar~~ molecular weight of between 750,000 and 890,000 Da, with an intrinsic viscosity of between 11.07dl/gm and 12.45 dl/gm.

Claims 34-35 (canceled)

Claim 36 (previously presented): The method according to Claim 33, wherein the hyaluronan has a molecular weight of 890,000 Da.

Claim 37 (canceled)

Claim 38 (previously presented): The method according to Claim 33, wherein the chemotherapeutic agent is selected from the group consisting of methotrexate, paclitaxel, 5-fluorouracil and cyclophosphamide.

Claim 39 (currently amended): A method for overcoming acquired resistance of cancer cells to a chemotherapeutic agent, said method comprising administering ~~systemically~~ intravenously to a subject having said resistant cancer cells a hyaluronan and said chemotherapeutic agent, wherein the hyaluronan has a ~~molar~~ molecular weight of between 750,000 and 890,000 Da, with an intrinsic viscosity of between 11.07dl/gm and 12.45 dl/gm.

Claims 40-41 (canceled)

Claim 42 (previously presented): The method according to Claim 39, wherein the hyaluronan has a molecular weight of 890,000 Da.

Claim 43 (canceled)

Claim 44 (previously presented): The method according to Claim 39, wherein the chemotherapeutic agent is selected from the group consisting of methotrexate, paclitaxel, 5-fluorouracil and cyclophosphamide.

Claim 45 (currently amended): A pharmaceutical composition formulated for ~~systemic~~ intravenous administration consisting essentially of an anticancer chemotherapeutic agent and hyaluronan, wherein the hyaluronan has a ~~molar~~ molecular weight of between 750,000 and 890,000 Da, with an intrinsic viscosity of between 11.07dl/gm and 12.45 dl/gm.

Claims 46-47 (canceled)

Claim 48 (previously presented): The pharmaceutical composition of Claim 45, wherein the hyaluronan has a molecular weight of 890,000 Da.

Claim 49 (canceled)

Claim 50 (previously presented): The pharmaceutical composition of Claim 45, wherein the chemotherapeutic agent is selected from the group consisting of methotrexate, paclitaxel, 5-fluorouracil and cyclophosphamide.

Claim 51 (currently amended): A pharmaceutical composition formulated for ~~systemic~~ intravenous administration comprising an anticancer chemotherapeutic agent and hyaluronan having ~~molecular weight of modal~~ a molecular weight of between 750,000 and 890,000 Da, with an intrinsic viscosity of between 11.07dl/gm and 12.45 dl/gm.

Claim 52 (previously presented): The pharmaceutical composition of Claim 51, wherein the hyaluronan has molecular weight 890,000 Da.

Claims 53-56 (canceled)

Claim 57 (previously presented): The method of claim 27, wherein the hyaluronan has a polydispersity of 1.78.

Claim 58 (previously presented): The method of claim 33, wherein the hyaluronan has a polydispersity of 1.78.

Claims 59-60 (canceled)

Claim 61 (previously presented): The pharmaceutical composition of claim 45, wherein the hyaluronan has a polydispersity of 1.78.

Claim 62 (canceled)

Claim 63 (new): The pharmaceutical composition of claim 45, wherein the hyaluronan has a modal molecular weight of 890,000 Da.

Claim 64 (new): The pharmaceutical composition of claim 45, wherein the hyaluronan has a molecular weight of 750,000 Da.

Claim 65 (new): The pharmaceutical composition of claim 51, wherein the hyaluronan has a modal molecular weight of 890,000 Da.

Claim 66 (new): The pharmaceutical composition of claim 51, wherein the hyaluronan has a molecular weight of 750,000 Da.

Claim 67 (new): The pharmaceutical composition of claim 51, wherein the hyaluronan has a polydispersity of 1.78.

Claim 68 (new): The method according to Claim 27, wherein the hyaluronan has a modal molecular weight of 890,000 Da.

Claim 69 (new): The method according to Claim 33, wherein the hyaluronan has a modal molecular weight of 890,000 Da.

Claim 70 (new): The method according to Claim 39, wherein the hyaluronan has a modal molecular weight of 890,000 Da.

Claim 71 (new): The method according to Claim 27, wherein the hyaluronan has a molecular weight of 750,000 Da.

Claim 72 (new): The method according to Claim 33, wherein the hyaluronan has a molecular weight of 750,000 Da.

Claim 73 (new): The method according to Claim 39, wherein the hyaluronan has a molecular weight of 750,000 Da.